What is the share price of Astal Laboratories Ltd (ASTALLTD) today?
The share price of ASTALLTD as on 16th September 2026 is ₹73.20. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Astal Laboratories Ltd (ASTALLTD) share?
The past returns of Astal Laboratories Ltd (ASTALLTD) share are- Past 1 week: -5.55%
- Past 1 month: -16.70%
- Past 3 months: -11.58%
- Past 6 months: 1.39%
- Past 1 year: -13.13%
- Past 3 years: 128.39%
- Past 5 years: 545.50%
What are the peers or stocks similar to Astal Laboratories Ltd (ASTALLTD)?
The peers or stocks similar to Astal Laboratories Ltd (ASTALLTD) include:What is the market cap of Astal Laboratories Ltd (ASTALLTD) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Astal Laboratories Ltd (ASTALLTD) is ₹328.36 Cr as of 16th September 2026.What is the 52 week high and low of Astal Laboratories Ltd (ASTALLTD) share?
The 52-week high of Astal Laboratories Ltd (ASTALLTD) is ₹103.20 and the 52-week low is ₹60.45.What is the PE and PB ratio of Astal Laboratories Ltd (ASTALLTD) stock?
The P/E (price-to-earnings) ratio of Astal Laboratories Ltd (ASTALLTD) is 22.32. The P/B (price-to-book) ratio is 9.12.Which sector does Astal Laboratories Ltd (ASTALLTD) belong to?
Astal Laboratories Ltd (ASTALLTD) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Astal Laboratories Ltd (ASTALLTD) shares?
You can directly buy Astal Laboratories Ltd (ASTALLTD) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Astal Laboratories Ltd
ASTALLTD Share Price
BSE₹73.202.36% (-1.77)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
ASTALLTD Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
ASTALLTD Performance & Key Metrics
ASTALLTD Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 14.78 | 9.12 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 46.29 | 5.81 | 0.49% |
ASTALLTD Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
ASTALLTD Company Profile
Astal Laboratories Ltd is engaged in the pharmaceutical bulk drug business, owning a manufacturing plant for pharmaceutical intermediates in Karnataka.
SUNPHARMA
PE Ratio
38.35
38.35
1Y Return
15.08%
15.08%
Buy Reco %
93.55
93.55
TORNTPHARM
PE Ratio
85.27
85.27
1Y Return
36.60%
36.60%
Buy Reco %
81.48
81.48
ZYDUSLIFE
PE Ratio
21.75
21.75
1Y Return
6.59%
6.59%
Buy Reco %
57.69
57.69
CIPLA
PE Ratio
28.13
28.13
1Y Return
12.89%
12.89%
Buy Reco %
62.86
62.86
LAURUSLABS
PE Ratio
117.14
117.14
1Y Return
112.52%
112.52%
Buy Reco %
58.33
58.33
ASTALLTD Forecast
ASTALLTD Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
ASTALLTD
ASTALLTD
Income
Balance Sheet
Cash Flow
Quarterly Normal View
ASTALLTD Income Statement
ASTALLTD Income Statement
Quarterly Normal View
| Quarter | mar 2025 | dec 2025 | mar 2026 | jun 2026 | ||||
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 23.50 | 52.27 | 134.15 | 101.07 | ||||
Operating & Other expenses | 19.28 | 48.68 | 123.86 | 88.69 | ||||
EBITDA | 4.22 | 3.59 | 10.29 | 12.38 | ||||
| Depreciation/Amortization | 0.10 | 0.12 | 0.86 | 0.86 | ||||
| PBIT | 4.12 | 3.47 | 9.43 | 11.52 | ||||
| Interest & Other Items | 0.27 | 0.33 | 1.09 | 1.18 | ||||
| PBT | 3.85 | 3.14 | 8.34 | 10.34 | ||||
| Taxes & Other Items | 1.10 | 0.77 | 0.66 | 0.93 | ||||
| Net Income | 2.75 | 2.37 | 7.68 | 9.41 | ||||
| EPS | 2.80 | 2.19 | 2.04 | 2.19 |
ASTALLTD Company Updates
ASTALLTD Stock Peers
ASTALLTD Past Performance & Peer Comparison
ASTALLTD Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Astal Laboratories Ltd | 22.32 | 9.12 | — |
| Sun Pharmaceutical Industries Ltd | 38.35 | 5.25 | 0.87% |
| Torrent Pharmaceuticals Ltd | 85.27 | 10.49 | 0.70% |
| Zydus Lifesciences Ltd | 21.75 | 3.71 | 0.09% |
ASTALLTD Stock Price Comparison
Compare ASTALLTD with any stock or ETFCompare ASTALLTD with any stock or ETF
ASTALLTD
ASTALLTD Holdings
ASTALLTD Shareholdings
ASTALLTD Promoter Holdings Trend
ASTALLTD Promoter Holdings Trend
Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has decreased by 13.66%
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
ASTALLTD Institutional Holdings Trend
ASTALLTD Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding Pattern
ASTALLTD Shareholding History
ASTALLTD Shareholding History
Foreign Institutions
smallcases containing ASTALLTD stock
smallcases containing ASTALLTD stock
Looks like this stock is not in any smallcase yet.
ASTALLTD Events
ASTALLTD Events
ASTALLTD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASTALLTD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
ASTALLTD Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
ASTALLTD has not given any dividends in last 5 years
ASTALLTD Dividends
ASTALLTD Dividends
Hmm, looks like data is unavailable here. Please come back after some timeASTALLTD Stock News & Opinions
ASTALLTD Stock News & Opinions
Articles & Videos
Corporate
Corporate
Astal Laboratories to convene board meeting in Telangana on September 4, 2026Astal Laboratories Limited will hold a meeting of its Board of Directors on September 4, 2026, at its corporate office in Telangana to consider and approve the notice for the company’s 33rd Annual General Meeting, approve the Board Report for the financial year ended March 31, 2026, and appoint a scrutinizer for the AGM and remote e-voting.
2 weeks agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meeting August 14 to review quarterly financial resultsAstal Laboratories Limited will hold a meeting of its Board of Directors on August 14, 2026, at its corporate office in Telangana to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with a Limited Review Report from the auditors.
1 month agoCapital Market - Live
Earnings
Earnings
Astal Laboratories consolidated net profit rises 180.29% in the March 2026 quarterNet profit of Astal Laboratories rose 180.29% to Rs 7.68 crore in the quarter ended March 2026 as against Rs 2.74 crore during the previous quarter ended March 2025. Sales rose 471.15% to Rs 134.05 crore in the quarter ended March 2026 as against Rs 23.47 crore during the previous quarter ended March 2025. For the full year,net profit rose 64.73% to Rs 14.71 crore in the year ended March 2026 as against Rs 8.93 crore during the previous year ended March 2025. Sales rose 287.87% to Rs 249.13 crore in the year ended March 2026 as against Rs 64.23 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.0523.47 471 249.1364.23 288 OPM %7.6017.81 -8.3419.88 - PBDT9.203.95 133 18.9612.20 55 PBT8.343.85 117 17.7311.98 48 NP7.682.74 180 14.718.93 65 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to convene board meetingAstal Laboratories will hold a meeting of the Board of Directors of the Company on 30 May 2026.
3 months agoCapital Market - Live
Earnings
Earnings
Astal Laboratories standalone net profit declines 5.22% in the December 2025 quarterNet profit of Astal Laboratories declined 5.22% to Rs 2.36 crore in the quarter ended December 2025 as against Rs 2.49 crore during the previous quarter ended December 2024. Sales rose 261.27% to Rs 52.24 crore in the quarter ended December 2025 as against Rs 14.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales52.2414.46 261 OPM %6.7822.96 - PBDT3.253.10 5 PBT3.133.02 4 NP2.362.49 -5 Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to conduct board meetingAstal Laboratories will hold a meeting of the Board of Directors of the Company on 14 February 2026.Powered by Capital Market - Live
7 months agoCapital Market - Live
Earnings
Earnings
Astal Laboratories standalone net profit rises 29.00% in the September 2025 quarterNet profit of Astal Laboratories rose 29.00% to Rs 2.58 crore in the quarter ended September 2025 as against Rs 2.00 crore during the previous quarter ended September 2024. Sales rose 185.11% to Rs 37.52 crore in the quarter ended September 2025 as against Rs 13.16 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales37.5213.16 185 OPM %10.2921.96 - PBDT3.582.80 28 PBT3.462.77 25 NP2.582.00 29 Powered by Capital Market - Live
9 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to declare Quarterly ResultsAstal Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2025.Powered by Capital Market - Live
10 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to conduct EGMAstal Laboratories announced that an Extra Ordinary General Meeting (EGM) of the Company will be held on 6 November 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Corporate
Corporate
Astal Laboratories to conduct board meetingAstal Laboratories will hold a meeting of the Board of Directors of the Company on 9 October 2025.Powered by Capital Market - Live
11 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 316.06%, vs industry avg of 11.79%
Over the last 5 years, market share increased from 0% to 0.05%
Over the last 5 years, net income has grown at a yearly rate of 385091.31%, vs industry avg of 10.53%